Another recent study showed lower major or clinically relevant non-major bleeding in AF patients who underwent PCI who used dabigatran and a P2Y12 inhibitor (clopidogrel or ticagrelor) when compared to the triple antithrombotic therapy (warfarin, aspirin, and a P2Y12 inhibitor) over a mean 14 months follow-up. This evidence concerns the gene P2RY12 and atrial fibrillation.